

**Rabbit Anti-ARID1A/BAF250A/NAA10 [EP303]: RM0353, RM0353RTU7**

**Intended Use:** For Research Use Only

**Description:** ARID1A (AT-rich interactive domain-containing protein 1A), also known as BAF250a, is a recently identified tumor suppressor that is a component of the SWI/SNF chromatin remodeling complex. ARID1A functions by binding AT-rich DNA sequences to regulate gene expression of nucleosome mobilization and chromatin processes. While ARID1A is typically expressed in most normal tissues, it is frequently mutated in a multitude of tumors, including breast, lung, gastric, renal and ovarian cancers. Genomic sequencing revealed that most ARID1A mutations are truncating mutations, and the presence of mutations is highly correlative with loss of ARID1A protein expression by immunohistochemistry. Deficient ARID1A expression was observed in approximately 70% of renal cell carcinomas, 50% of gastric cancers, 40% of clear cell ovarian carcinomas, and 40% of endometrioid carcinomas. Furthermore, loss of ARID1A expression was determined as an independent marker for poor prognosis; tumors were correlated with higher stage and grade, are more likely to be chemoresistant, and associated with shorter progression-free and overall survival rates. ARID1A antibody may be used for identifying ARID1A defect tumors.


**Specifications**

Clone: EP303  
 Source: Rabbit  
 Isotype: IgG  
 Reactivity: Human  
 Localization: Nucleus  
 Formulation: Antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN<sub>3</sub>)  
 Storage: Store at 2°- 8°C  
 Applications: IHC  
 Package:

Description	Catalog No.	Size
ARID1A/BAF250A/NAA10 Concentrated	RM0353	1 ml
ARID1A/BAF250A/NAA10 Prediluted	RM0353RTU7	7 ml

**IHC Procedure**

Positive Control: Colon  
 Concentrated Dilution: 50-200  
 Pretreatment: Citrate pH6.0 or EDTA pH8.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C  
 Incubation Time and Temp: 30-60 minutes @ RT  
 Detection: Refer to the detection system manual  
 \* Result should be confirmed by an established diagnostic procedure.



FFPE human endometrial carcinoma tissue stained with anti-ARID1A using DAB

**References:**

1. Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. Luchini C, et al. Oncotarget. Nov 17;6(36):39088-97, 2015.
2. ARID1A is a useful marker of malignancy in peritoneal washings for endometrial carcinoma. Nagymanyoki Z, et al. Cancer Cytopathol. Apr;123(4):253-7, 2015.

Doc. 100-RM0353  
Rev. A